Use of Commercial Genomic Testing for Prostate Cancer ‘Highly Variable’ in the United States
Investigators evaluated a large sample of commercially insured patients with prostate cancer to assess use of tissue-based gene expression testing.
Investigators evaluated a large sample of commercially insured patients with prostate cancer to assess use of tissue-based gene expression testing.
Although some tumors lack aneuploidy or have few extra chromosomal copies, others have a slew of mutations.
The research findings could lead to the development of new therapeutic targets.
New cancer-specific designs are needed to balance out heart and cancer outcomes in the chronic disease setting of CLL.
Head-to-head comparisons of these types of surgical interventions are still needed, according to the regulatory body.
Researchers are excited about the prospect to use vaccines in combination with checkpoint inhibitors to improve the body’s cancer-fighting ability.
Use of experimental T cells that target Epstein-Barr virus proteins in relapsed or refractory lymphoma may improve overall survival.
A new model has the potential to identify patients with melanoma who could benefit from treatment with checkpoint inhibitors.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
According to experts, PARP inhibition, radiopharmaceuticals, and immunotherapy could revolutionize how prostate cancer is treated in the coming decade.